Accessibility Menu
Astellas Pharma logo

Astellas Pharma(OTC) ALPMF

Current Price$12.85
Market Cap$25.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-46%
5 Year-12%
1 Year+43%
1 Month-12%
Astellas Pharma last closing stock price
MetricPriceDate
Last closeUSD 12.852026-07-21
Astellas Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 12.852026-07-14
1 month-11.99%USD 14.602026-06-18
3 month-18.41%USD 15.752026-04-22
Year to date-0.93%USD 12.972025-12-30
1 year+43.1%USD 8.982025-07-18
3 year-2.37%USD 13.162023-07-21
5 year-11.83%USD 14.572021-07-20
Since inception-45.78%USD 26.742003-07-15

Astellas Pharma Financials at a Glance

Market Cap

$25.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥2.15T

Net Income (TTM)

¥293.07B

EPS (TTM)

$1.08

P/E Ratio

13.39

Dividend

$0.51

Beta (Volatility)

0.06 (Low)

Price

$12.85

Volume

538

Open

$12.85

Previous Close

$12.85

Daily Range

$12.85 - $12.85

52-Week Range

$9.34 - $17.85

Estimated Earnings Date

Aug 5, 2026

ALPMF News

GettyImages-1146913659

A $20 Billion Sweet Spot in Biotech

David HaenDec 28, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Astellas Pharma

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, focusing on the development, manufacturing, distribution, and commercialization of medicinal products. The company is known for its innovative therapies targeting various medical conditions, including cancer and chronic diseases.

Products and Services
  • XTANDI for prostate cancer treatment
  • XOSPATA for acute myeloid leukemia
  • PADCEV for urothelial cancer
Growth Outlook
  • Recent collaborations with leading firms enhance research capabilities
  • Focus on innovative therapies positions Astellas for market expansion
  • Strong pipeline of products supports long-term growth potential
Financial Highlights
  • TTM revenue of 2.2 trillion JPY, reflecting robust sales performance
  • Net income of 438.9 billion JPY in the latest quarter
  • Operating income margin of 14.5% indicates efficient operations
Astellas Pharma Inc. has established itself as a key player in the pharmaceutical industry, with a diverse portfolio of products that address significant health challenges. The company's commitment to research and development is evident through its strategic alliances and collaborations, which aim to foster innovation and enhance therapeutic offerings. Recent financial performance showcases a strong revenue base and profitability, positioning Astellas favorably for future growth. The focus on expanding its product pipeline and entering new markets further underscores the company's potential for sustained success in the competitive pharmaceutical landscape.
AI Generated • Jun 22, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14,099

CEO

Naoki Okamura

Website

www.astellas.com

Headquarters

Tokyo, TY 103-8411, JP

ALPMF Financials

Key Financial Metrics (TTM)

Gross Margin

76.08%

Operating Margin

18.92%

Net Income Margin

13.63%

Return on Equity

17.44%

Return on Capital

17.51%

Return on Assets

8.17%

Earnings Yield

7.47%

Dividend Yield

3.51%

Payout Ratio

46.68%

Stock Overview

Market Cap

$25.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.79B

Volume

538

Avg. Volume

5.80K

Financials (TTM)

Gross Profit

¥1.64T

Operating Income

¥406.98B

EBITDA

¥622.98B

Operating Cash Flow

¥569.87B

Capital Expenditure

-¥58.03B

Free Cash Flow

¥511.84B

Cash & ST Invst.

¥283.38B

Total Debt

¥569.51B

Astellas Pharma Performance Analysis

Astellas Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 11,210,593,310-2.8%
20242024-03-31JPY 11,104,729,504-0.9%
20252025-03-31JPY 12,543,905,53613.0%
20262026-03-31JPY 14,196,133,79713.2%
Astellas Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3010.1%
Q22025-09-305.1%
Q32025-12-317.5%
Q42026-03-31-5.3%
Astellas Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.40-33.1%
20242024-03-31JPY 0.07-83.6%
20252025-03-31JPY 0.19182.3%
20262026-03-31JPY 1.08481.3%
Astellas Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-30-7.5%
Q22025-09-3017.3%
Q32025-12-3125.1%
Q42026-03-31-57.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

¥541.31B

+17.9%

Gross Profit

¥411.07B

+7.5%

Gross Margin

75.94%

N/A

Market Cap

$25.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.84M

N/A

Employees

14,099

N/A

Net Income

¥43.89B

-41.4%

EBITDA

¥129.02B

+26.8%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

¥283.38B

+29.8%

Total Debt

¥569.51B

-31.5%

Accounts Receivable

¥766.56B

+21.2%

Inventory

¥333.10B

+12.1%

Long Term Debt

¥322.01B

-43.0%

Short Term Debt

¥247.50B

-7.1%

Return on Assets

8.17%

N/A

Return on Invested Capital

17.24%

N/A

Free Cash Flow

¥189.72B

+107.6%

Operating Cash Flow

¥206.42B

+104.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ORINYOrion Oyj
$43.02+2.20%
WXXWYWuXi Biologics (Cayman) Inc.
$9.81+0.31%
WXIBFWuXi Biologics (Cayman) Inc.
$4.60+0.00%
GNMSFGenmab A/S
$274.50-2.66%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.26+0.01%
NOKNokia
$10.63+0.05%
AALAmerican Airlines Group
$15.28+0.01%
SOFISoFi Technologies
$17.64+0.04%

Questions About ALPMF

What is the current price of Astellas Pharma?

Astellas Pharma is trading at $12.85 per share.

What is the 52-week range for Astellas Pharma?

Over the past 52 weeks, Astellas Pharma has traded between $9.34 and $17.85.

How much debt does Astellas Pharma have?

As of the most recent reporting period, Astellas Pharma reported total debt of ¥4.23B.

How much cash does Astellas Pharma have on hand?

Astellas Pharma reported ¥1.77B in cash and cash equivalents in its most recent financial results.

What is Astellas Pharma’s dividend yield?

Astellas Pharma currently has a dividend yield of 3.51%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services